Does it excite you to lead late-stage analytical development for innovative peptide-based medicines, and do you have a strong technical background in analytical science? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
Your new position
As Lead Analytical Specialist, you will lead late-stage analytical development and provide scientific and technical direction across a broad range of activities in Development and Life Cycle Management projects. Given our collaboration with Contract Development and Manufacturing Organizations (CDMO), effective coordination with external partners is a significant aspect of this role.
We offer exciting responsibilities:
Your profile
We are looking for someone with an analytical mindset who takes ownership of complex initiatives, communicates clearly across teams, and enjoys mentoring others while continuously learning. You bring strong collaboration skills and a proactive approach to problem-solving.
Your new team
You will be joining a highly experienced team of experts within CMC Development, acting as a technical point of reference and mentor for colleagues. We value a collaborative and supportive atmosphere where we achieve great results together.
Let's bond and be bold
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.
Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.
Interested in bonding with us? Then please apply no later than August 23, 2026, or as soon as possible. The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.
For further information, please contact Director, Head of Drug Substance & Analysis, Iben Almar Meier; imeier@zealandpharma.com
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com
#LI-Onsite
At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines.
In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other.
Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases.
Our leading obesity programs are backed by strong partners, including Roche and Boehringer Ingelheim.
We are based in Copenhagen (Søborg), Denmark, with a team in the U.S. For further information about our business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.
